glp-1 therapy protein intake optimization Nutritional and lifestyle supportive care recommendations for management of obesity with - based therapies: An expert consensus statement using a modified Delphi approach Optimizing GLP-1 therapies for obesity

(43(2)):290-296 doi:10.1002/jimd.12158

The same greater than 99% purity standard applies to the 20mg product

10,11 This compositional change affects host metabolism via the gutliver axis: conjugated bile acids act as antagonists of FXR in the intestine, inhibiting the intestinal FXR-FGF15/19 signaling pathway, leading to upregulation of hepatic cholesterol 7-hydroxylase expression and accelerating the conversion of cholesterol to bile acids, but may also promote hepatic lipogenesis

Cureus 16 (7), e64629 (2024)

Moreover, repeated administration of PEGylated products may produce PEG antibodies, potentially reducing drug efficacy